Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) Consolidated Net Income: 2019-2025

Historic Consolidated Net Income for Avidity Biosciences (RNA) over the last 7 years, with Sep 2025 value amounting to -$174.1 million.

  • Avidity Biosciences' Consolidated Net Income fell 117.13% to -$174.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$548.5 million, marking a year-over-year decrease of 95.95%. This contributed to the annual value of -$322.1 million for FY2024, which is 52.18% down from last year.
  • Avidity Biosciences' Consolidated Net Income amounted to -$174.1 million in Q3 2025, which was down 11.11% from -$156.7 million recorded in Q2 2025.
  • In the past 5 years, Avidity Biosciences' Consolidated Net Income registered a high of -$23.8 million during Q1 2021, and its lowest value of -$174.1 million during Q3 2025.
  • Moreover, its 3-year median value for Consolidated Net Income was -$70.7 million (2024), whereas its average is -$89.1 million.
  • Data for Avidity Biosciences' Consolidated Net Income shows a maximum YoY tumbled of 291.80% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Avidity Biosciences' Consolidated Net Income stood at -$38.5 million in 2021, then crashed by 31.07% to -$50.5 million in 2022, then decreased by 19.59% to -$60.3 million in 2023, then tumbled by 69.81% to -$102.5 million in 2024, then crashed by 117.13% to -$174.1 million in 2025.
  • Its Consolidated Net Income stands at -$174.1 million for Q3 2025, versus -$156.7 million for Q2 2025 and -$115.3 million for Q1 2025.